|
US6551632B2
(en)
*
|
1997-04-01 |
2003-04-22 |
Thomas Julius Borody |
Methods and compositions for treating inflammatory bowel disease
|
|
AUPP325398A0
(en)
|
1998-04-30 |
1998-05-21 |
Borody, Thomas J. |
Improved method for eradicating h. pylori
|
|
JP2002536404A
(ja)
*
|
1999-02-12 |
2002-10-29 |
ワシントン ユニバーシティー |
炎症性腸疾患を治療するための好中球機能の刺激
|
|
CA2387016C
(en)
*
|
1999-10-08 |
2010-09-28 |
William H. Miller |
Acrylamide derivatives as fab i inhibitors
|
|
JP3369535B2
(ja)
|
1999-11-09 |
2003-01-20 |
松下電器産業株式会社 |
プラズマディスプレイ装置
|
|
US7638496B2
(en)
|
2000-02-15 |
2009-12-29 |
Valeant Pharmaceuticals North America |
Nucleoside analogs with carboxamidine modified monocyclic base
|
|
DE60138876D1
(de)
*
|
2000-03-28 |
2009-07-16 |
Sandoz Ag |
Geschmackmaskierte granulierte teilchen
|
|
AU2001285311B2
(en)
|
2000-08-29 |
2005-09-15 |
Biocon, Ltd |
Immunoregulatory compounds, derivatives thereof and their use
|
|
WO2003088897A2
(en)
*
|
2001-04-06 |
2003-10-30 |
Affinium Pharmaceuticals, Inc. |
Fab i inhibitors
|
|
US8048924B2
(en)
|
2001-08-29 |
2011-11-01 |
Biocon Limited |
Methods and compositions employing 4-aminophenylacetic acid compounds
|
|
US20030118329A1
(en)
*
|
2001-12-21 |
2003-06-26 |
Pere Obrador |
Video indexing using high resolution still images
|
|
AUPS088702A0
(en)
*
|
2002-03-04 |
2002-03-28 |
Borody, Thomas Julius |
Electrolyte purgative
|
|
EP1575951B1
(en)
*
|
2002-12-06 |
2014-06-25 |
Debiopharm International SA |
Heterocyclic compounds, methods of making them and their use in therapy
|
|
WO2004082586A2
(en)
|
2003-03-17 |
2004-09-30 |
Affinium Pharmaceuticals, Inc. |
Phamaceutical compositions comprising inhibitors of fab i and further antibiotics
|
|
US6930093B2
(en)
*
|
2003-07-10 |
2005-08-16 |
Valeant Research & Development |
Use of ribofuranose derivatives against inflammatory bowel diseases
|
|
WO2005046567A2
(en)
*
|
2003-09-10 |
2005-05-26 |
Meena Shelgaonkar |
Synergistic formulation of antioxidants and antimycobacterial agents: a method of making the same
|
|
AU2004314731B2
(en)
*
|
2004-01-20 |
2011-07-07 |
The Board Of Regents Of The University Of Oklahoma |
Compositions and methods of treatment for inflammatory diseases
|
|
EP1720536B1
(en)
|
2004-02-06 |
2012-04-25 |
PHARMATEL (R&D) PTY LIMITED as Trustee for the PHARMATEL (R & D) TRUST |
Use of aminosalicylates in diarrhoea-predominent irritable bowel syndrome
|
|
JP5009152B2
(ja)
*
|
2004-05-28 |
2012-08-22 |
サリックス ファーマシューティカルズ， インコーポレイテッド |
放射線誘発性腸炎の予防、処置、および回復
|
|
PL1828167T3
(pl)
*
|
2004-06-04 |
2015-02-27 |
Debiopharm Int Sa |
Pochodne akryloamidu jako środki antybiotykowe
|
|
DK1773767T3
(en)
|
2004-07-07 |
2016-03-21 |
Biocon Ltd |
Synthesis of azo bound in immune regulatory relations
|
|
CA2816276A1
(en)
*
|
2005-08-24 |
2007-03-01 |
Salix Pharmaceuticals, Inc. |
Balsalazide formulations and manufacture and use thereof
|
|
US7452872B2
(en)
*
|
2005-08-24 |
2008-11-18 |
Salix Pharmaceuticals, Inc. |
Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
|
|
US8921344B2
(en)
*
|
2006-11-03 |
2014-12-30 |
Salix Pharmaceuticals, Inc. |
Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
|
|
WO2007067416A2
(en)
*
|
2005-12-05 |
2007-06-14 |
Affinium Pharmaceuticals, Inc. |
Heterocyclylacrylamide compounds as fabi inhibitors and antibacterial agents
|
|
CA2531261A1
(en)
*
|
2005-12-21 |
2007-06-21 |
Institut Pasteur |
Control of intestinal inflammatory syndromes with a preparation of killed or non infectious bacteria
|
|
EP2054422B1
(en)
|
2006-07-20 |
2017-06-14 |
Debiopharm International SA |
Acrylamide derivatives as fab i inhibitors
|
|
EP3255045A1
(en)
*
|
2007-02-16 |
2017-12-13 |
Debiopharm International SA |
Salts, prodrugs and polymorphs of fab i inhibitors
|
|
US8436051B2
(en)
|
2007-06-08 |
2013-05-07 |
Aptalis Pharma Canada Inc. |
Mesalamine suppository
|
|
US7541384B2
(en)
|
2007-06-08 |
2009-06-02 |
Axcan Pharma Inc. |
Mesalamine suppository
|
|
US8217083B2
(en)
*
|
2007-06-08 |
2012-07-10 |
Aptalis Pharma Canada Inc. |
Mesalamine suppository
|
|
JP2011500552A
(ja)
*
|
2007-10-10 |
2011-01-06 |
ルピン・リミテッド |
胃腸障害を処置するための医薬用組み合わせおよび組成物
|
|
US20090098088A1
(en)
*
|
2007-10-10 |
2009-04-16 |
The Procter & Gamble Company |
Methods And Kits For The Treatment Of Diverticular Conditions
|
|
WO2009064953A1
(en)
*
|
2007-11-15 |
2009-05-22 |
Enanta Pharmaceuticals, Inc. |
Use of bridged macrolides or tylosin derivatives in treating inflammatory bowel diseases
|
|
WO2009097651A1
(en)
|
2008-02-08 |
2009-08-13 |
Giaconda Limited |
Methods and compositions for treating inflammatory bowel disease
|
|
RU2010143460A
(ru)
*
|
2008-05-01 |
2012-06-10 |
Дзе Проктер Энд Гэмбл Компани (US) |
Способы и наборы для терапии восстановительных состояний кишечника
|
|
WO2011044140A1
(en)
*
|
2009-10-05 |
2011-04-14 |
Catabasis Pharmaceuticals, Inc. |
Substituted thioacetic acid salicylate derivatives and their uses
|
|
AU2010312309B2
(en)
|
2009-10-26 |
2016-10-06 |
Thomas Julius Borody |
Novel enteric combination therapy
|
|
AU2011245455A1
(en)
|
2010-04-26 |
2012-11-15 |
Salix Pharmaceuticals, Ltd. |
Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives for the treatment of males
|
|
MX355760B
(es)
|
2010-12-13 |
2018-04-27 |
Salix Pharmaceuticals Inc |
Formulaciones gástricas y colónicas y métodos para elaborar y usar las mismas.
|
|
TWI573590B
(zh)
*
|
2011-09-20 |
2017-03-11 |
雷希爾生藥有限公司 |
治療自體免疫疾病之組成物及方法
|
|
JP6085026B2
(ja)
|
2012-06-19 |
2017-02-22 |
デビオファーム インターナショナル エスエーＤｅｂｉｏｐｈａｒｍ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｓａ |
（ｅ）−ｎ−メチル−ｎ−（（３−メチルベンゾフラン−２−イル）メチル）−３−（７−オキソ−５，６，７，８−テトラヒドロ−１，８−ナフチリジン−３−イル）アクリルアミドのプロドラッグ誘導体
|
|
DK2877163T3
(en)
|
2012-07-27 |
2019-04-15 |
Redhill Biopharma Ltd |
FORMULATIONS AND PROCEDURES FOR THE PREPARATION OF FORMS FOR USING GAS DRAINAGE
|
|
WO2015179809A1
(en)
|
2014-05-22 |
2015-11-26 |
Kuenstner John Todd |
Treatment of diseases using combination of ultraviolet blood irradiation and antibiotics
|
|
US10751351B2
(en)
|
2016-02-26 |
2020-08-25 |
Debiopharm International S.A. |
Medicament for treatment of diabetic foot infections
|
|
WO2022003421A2
(en)
|
2020-06-30 |
2022-01-06 |
Redhill Biopharma Ltd. |
Triple antibiotic fixed-dose combination products, dosing regimen, methods, and kits for treating pulmonary non-tuberculosis mycobacterial infections
|
